Searchable abstracts of presentations at key conferences in endocrinology

ea0084ps2-07-63 | Graves’ Disease 1 | ETA2022

Corticosteroids and mycophenolic acid have a synergistic effect on chemokines secretion in orbital cells from patients with graves’ ophthalmopathy

Martina Ferrari Silvia , Fallahi Poupak , Ragusa Francesca , Elia Giusy , Rosaria Paparo Sabrina , Patrizio Armando , Balestri Eugenia , Antonelli Alessandro

Objective: An enhancement of the response rate has been recently showed in patients with Graves’ ophthalmopathy (GO) treated with corticosteroids and mycophenolic acid. In GO, retro-orbital cells showed a cytokine-induced secretion of Th1 and Th2 chemokines. Since no data are present in literature about the effect of corticosteroids and mycophenolic acid on the chemokines secretion in GO orbital cells, we aim to deepen out this topic.Methods: We est...

ea0092ps3-25-07 | Case Reports 2 | ETA2023

A case report of graves’ disease induced by IFN-β-1a therapy

Patrizio Armando , Viva Tommaso , Martina Ferrari Silvia , Elia Giusy , Ragusa Francesca , Rosaria Paparo Sabrina , Antonelli Alessandro , Fallahi Poupak

The risk of thyroid dysfunction induced by Interferon (IFN)-β1b therapy, in particular in patients having preexisting thyroid autoimmune disorders (AITD), is well known. We report a case of a 60-year-old female, with a 15-year history of euthyroid autoimmune thyroiditis and a 3-year history of Multiple Sclerosis (MS), in care for the evaluation of hyperthyroidism. The patient started a specific immunomodulant IFN-β1a therapy (30 μg/week) twenty months before the...

ea0081ep1138 | Thyroid | ECE2022

Autoimmune thyroiditis and hypothyroidism: a personalized medical approach

Martina Ferrari Silvia , Ragusa Francesca , Elia Giusy , Paparo Sabrina Rosaria , Mazzi Valeria , Balestri Eugenia , Botrini Chiara , Patrizio Armando , Antonelli Alessandro , Fallahi Poupak

Autoimmune thyroid diseases (AITD) are organ specific autoimmune disorders with a T-cell-mediated immune attack directed against the thyroid. Hashimoto’s thyroiditis and Graves’ disease are the two principal AITD clinical presentations, which are characterized by hypothyroidism and thyrotoxicosis, respectively. We review the available data in literature about personalized medicine in patients with autoimmune thyroiditis (AT) and hypothyroidism. The synthetic Levothyr...

ea0092ps3-21-06 | Hypothyroidism | ETA2023

Liquid Levothyroxine (L-T4; vs. Tablet L-T4) mantains more stable tsh levels in hypothyroid patients

Fallahi Poupak , Martina Ferrari Silvia , Elia Giusy , Ragusa Francesca , Rosaria Paparo Sabrina , Balestri Eugenia , Botrini Chiara , Patrizio Armando , Mazzi Valeria , Antonelli Alessandro

Hypothyroidism is usually treated with levothyroxine (L-T4), that is present in different formulation. We aim to assess if hypothyroid patients have a better control of thyroid-stimulating hormone (TSH) levels by following a L-T4 therapy in a liquid formulation, with respect to the tablet formulation. We enrolled seven hundred hypothyroid patients treated with liquid L-T4, and three hundred and fifty hypothyroid subjects receiving tablet L-T4 (both groups were matched by age a...

ea0092ps3-21-09 | Hypothyroidism | ETA2023

Efficacy of oral liquid l-thyroxine (L-T4) in controlling hypothyroidism in patients submitted to total thyroidectomy

Ragusa Francesca , Fallahi Poupak , Martina Ferrari Silvia , Elia Giusy , Materazzi Gabriele , Rosaria Paparo Sabrina , Patrizio Armando , Mazzi Valeria , Miccoli Paolo , Antonelli Alessandro

Tablet levothyroxine (L-T4) is the common treatment for hypothyroidism. We aim to investigate the efficacy of L-T4 in liquid formulation in patients recently subjected to total thyroidectomy (without malabsorption or drug interference), with respect to L-T4 tablets. Eighty patients were treated with L-T4 in tablets, whereas one hundred and sixty received liquid L-T4 at the same dosage (1.5 mg/kg/day). All patients started the therapy the day after thyroidectomy, and the drugs ...

ea0092ps3-28-04 | Translational 2 | ETA2023

Effect of pazopanib in anaplastic thyroid cancer in primary culture

Martina Ferrari Silvia , Elia Giusy , Ragusa Francesca , Rosaria Paparo Sabrina , Mazzi Valeria , Patrizio Armando , Piaggi Simona , Baldini Enke , Centanni Marco , La Motta Concettina , Antonelli Alessandro , Fallahi Poupak

Anaplastic thyroid cancer (ATC) is usually treated with surgery, external hyperfractionated radiation therapy, and chemotherapy. However, because of the aggressiveness of this type of cancer, these treatments allow about 6-10 months of median survival. Therefore, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c-Kit, and its effect in primary human ATC cells (pATC) h...